Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer, Houston, TX, comments on the benefits of momelotinib in the treatment of myelofibrosis (MF), highlighting its mechanism of action and discussing data from the MOMENTUM trial (NCT04173494). Momelotinib inhibits both JAK1/2 and ALK2, which helps lower hepcidin, thus increasing the availability of iron for making red blood cells, resulting in improved anemia and transfusion independence. The Phase III MOMENTUM study comparing momelotinib to danazol reported significant improvements in symptoms and anemia for patients treated with momelotinib, and could potentially lead to the approval of this drug in the second-line setting. According to Dr Verstovsek, momelotinib could even become the first treatment option for patients in second line as it reduces anemia in contrast to other JAKi like ruxolitinib which induce anemia. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

свернуть